TY - T1的情感文字记忆加工缺陷在多发性硬化(P04.118) JF -神经学乔-神经病学SP - P04.118 LP - P04.118六世- 80 - 7补充AU -彼得罗Iaffaldan首页o AU -罗莎Viterbo盟-贝内黛塔Goretti AU -埃米利奥Portaccio AU -玛丽亚阿马托盟玛丽亚Trojano Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/P04.118.abstract N2 -目的:评估患者的非文字记忆临床孤立综合征(CIS)暗示多发性硬化症(MS)的复发性(RR),与健康对照组相比(HC)。背景:具有情感冲击力的信息比中性的信息更容易被召回。到目前为止还没有调查情绪记忆在MS患者。设计/方法:七十一例患者(N = 22 CIS (16 F;平均年龄32.1;平均疾病持续时间1.19]N = 49名RRMS [34 F;平均年龄38.1;意味着疾病持续时间13.44]),21岁,sex-matched HC。立即(长期存储(LTS);一致的长期检索[CLTR]);延迟回忆(延迟[D])被选择性提醒评估测试(SRT)。列表12感情重要的词汇被用来评估情感(E) SRT的变体。 Depressive symptoms were assessed by the Beck Depression Inventory.RESULTS: The prevalence of depression did not differ between RRMS and CIS (32.6 vs 27.3%). RRMS and CIS patients showed poorer verbal memory performances in comparison to HC in all the 3 SRT tasks (ANOVA: p<.05), but no difference was found between patients. No differences in the performances in both memory tests were found between depressed and non-depressed patients. Emotionally salient words were more recalled than neutral words by HC and CIS patients while performing the immediate recall tasks (E-LTS vs LTS: 52.48 vs 45.29 in HC; 42.82 vs 34.86 in CIS [p=.001]; E-CLTR vs CLTR: 44.14 vs 38.48 in HC; 29.86 vs 25.59 in CIS [p<.05]); delayed recall was not affected by emotional stimuli in both groups. In RRMS patients no differences were found between emotional and neutral stimuli in both the immediate and in the delayed recall tests.CONCLUSIONS: Our results confirm the emotional enhancement of verbal memory in HC, and showed for the first time a defective emotion processing of verbal memory in MS patients.Disclosure: Dr. Iaffaldano has nothing to disclose. Dr. Viterbo has received personal compensation for activities with Biogen Idec and Novartis. Dr. Goretti has received personal compensation for activities with Biogen Idec and Merck Serono. Dr. Goretti has received research support from Biogen Idec and Novartis. Dr. Portaccio has received personal compensation for activities with Biogen Idec, Bayer, and Merck Serono. Dr. Portaccio has received research support from Biogen Idec, Bayer Schering Pharma, Merck Serono and Sanofi Aventis. Dr. Amato has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer Schering Pharma, and Sanofi Aventis as a scientific advisory board member and as a speaker. Dr. Amato has received research support from Biogen Idec, Merck Serono, Bayer Schering Pharma and Sanofi Aventis. Dr.Trojano has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc., Biogen Idec, Novartis, and Bayer Schering. Dr. Trojano has received research supprot from Merck Serono, Biogen Idec, and Novartis.Wednesday, March 20 2013, 7:30 am-12:00 pm ER -